Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Finding the right balance of BRAF inhibition in melanoma.

Cancer discovery - 1 May 2014

Davies Michael A

Abstract excerpt

Paradoxical activation of the mitogen-activated protein kinase pathway can cause secondary malignancies in patients treated with inhibitors of BRAF(V600) proteins. Characterization of a patient with concurrent BRAF-mutant melanoma and NRAS-mutant leukemia treated intermittently with combined BRAF and MEK inhibition provides new insights into the potential clinical and molecular effects of this therapeutic strategy.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to GTP Phosphohydrolases

Share to Leukemia

Share to Melanoma

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 24795008
DOI: 10.1158/2159-8290.CD-14-0307

Genes

BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Finding the right balance of BRAF inhibition in melanoma.PMID 24795008Read ↗

Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma.Semantic proximity Read ↗

BRAF inhibitors in clinical oncologySemantic proximity Read ↗

RAF inhibitors that evade paradoxical MAPK pathway activation.Semantic proximity Read ↗

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.Semantic proximity Read ↗

Mechanism and inhibition of BRAF kinase.Semantic proximity Read ↗

Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling.Semantic proximity Read ↗

Dual Inhibition of MAPK and JAK2/STAT3 Pathways Is Critical for the Treatment of BRAF Mutant MelanomaSemantic proximity Read ↗

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant MelanomaSemantic proximity Read ↗

Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy-Paradoxical ERK Activation and Beyond.Semantic proximity Read ↗

Dosing of BRAK and MEK Inhibitors in Melanoma: No Point in Taking a Break.Semantic proximity Read ↗

Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.Semantic proximity Read ↗

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.